Articles tagged with B Lymphocytes
A team of Osaka University researchers identified a specific subset of B cells with higher affinity that preferentially commit to plasma cell fate. The study suggests that stable Tfh-GC B cell contacts are key for plasma cell-prone GC cell formation, providing valuable insights for vaccine development.
A study published in Immunity reveals that T follicular helper cells play a crucial role in determining the fate of B cells, with stronger interactions leading to plasma B cell formation. The researchers identified a subset of B cells expressing IRF4 and CD69 as precursors to plasma B cells.
Researchers at Cornell University developed a device that exposes human lymphomas to fluid flow similar to that in the lymphatics and parts of the lymph node. The team found that certain subsets of DLCBL lymphoma respond differently to fluid forces, regulating expression levels of adhesion proteins known as integrins and B-cell receptors.
Researchers found that soluble antibodies from B cells induce accumulation of myeloid-derived suppressor cells, which inhibit antitumor immune response and worsen cancer outcomes. Targeting antibody production may slow down tumor progression.
Researchers at Garvan Institute of Medical Research found that a population of 'bad' antibodies, usually silenced due to harm to the body, can be activated to fight disease. The 'redeemed' antibodies become powerful weapons to combat diseases evading the immune system by disguising themselves as normal body tissue.
A new study reveals that HIV-infected patients experience dysfunction in follicular helper T cells, which typically help fight off infection. The researchers found that these cells are not playing their usual role to defend against viral infections.
Scientists at the Medical University of South Carolina discovered a specific form of transforming growth factor-beta (TGF-beta) that binds to glycoprotein-A repetitions predominant (GARP), regulating B cell activity. The GARP:TGF-beta axis may serve as a diagnostic marker and therapeutic target for autoimmune diseases.
Researchers discovered a new mechanism by which live vaccines induce immunity through TLR8 recognition. This triggers protective immune responses and improves vaccine safety and efficacy. The study's findings have the potential to develop new vaccines combining the benefits of live and modern subunit vaccines.
A new study finds that the microRNA family miR-17-92 plays a critical role in regulating T-cell and B-cell pathogenicity, leading to chronic graft-vs-host disease. The research also suggests that blocking this miRNA may be an effective way to reduce cGVHD symptoms.
Scientists identified a mechanism of resistance to ibrutinib, a current treatment for non-Hodgkin lymphoma, and discovered a promising therapeutic target in three enzymes. Blocking these enzymes with masitinib completely ablated the B-cell receptor pro-tumorigenic signals.
B cells play a key role in helping neurons develop by stimulating axon myelination, suggesting a potential link between B cell dysfunction and neurodevelopmental disorders. The study found that specific B cell antibodies promote oligodendrocyte proliferation and neuron myelination.
A new study found that phosphorylation of IRE1 regulates its RIDD function, which is critical for antibody production in response to immunization. The research provides deeper understanding of the ER stress response and its implications in various human pathological conditions.
A study published in Nature Communications found that an oxygen sensor in the body reduces inflammation by activating HIF-1α, which inhibits excessive immune responses. This molecular mechanism could lead to new approaches for treating chronic inflammatory diseases such as arthritis and multiple sclerosis.
A recent study published in the Journal of Experimental Medicine reveals that a common CLL treatment may be less effective in patients with a specific protein marker. Combining ibrutinib with drugs blocking this protein could prevent tumor cells from sheltering in lymphoid organs, leading to improved patient outcomes.
Loss of Roquin leads to autoimmune disorders due to imbalance in Treg functions. Inactive Roquin primarily affects regulatory T cells' ability to control T cell activation.
Daily low doses of interleukin-2 (IL-2) have been found to be safe and beneficial for patients with chronic graft-versus-host disease, including significant improvements in pediatric patients. IL-2 therapy boosts the production of inflammation-damping Treg cells, providing a mechanism for promoting tolerance in patients with chronic GVHD.
A recent study by La Jolla Institute for Allergy and Immunology reveals that dengue immunity can confer protection against Zika virus. Cytotoxic T-cells have been identified as crucial in defending against both viruses, suggesting that vaccines targeting either dengue or Zika could be effective.
Researchers at Massachusetts General Hospital have found that mature B lymphocytes can greatly accelerate the healing of acute and chronic wounds in both healthy and diabetic skin. The treatment also improved tissue quality and reduced scarring. High numbers of a patient's B cells can be isolated through standard blood pheresis procedu...
A Penn study found that Notch gene mutations drive expression of Myc and other genes in B-cell cancers, offering new insights into cancer growth and potential therapeutic targets. The research may lead to more effective treatment combinations by targeting Notch-Myc signaling pathways.
Researchers at the University of Pennsylvania discovered a dynamic two-step mechanism in female immune cells to regulate X chromosome inactivation. B cells regain X-chromosome markers during activation through the transcription factor YY1, leading to increased gene expression related to immunity.
Researchers identify regulatory T cells containing replication-competent virus in lymph nodes and gut, providing a strong rationale for targeting CTLA4. The discovery could help design immunotherapies to purge the viral reservoir and induce a stronger antiviral immune response.
Monash University researchers identified PRMT1 as an enzyme essential for the immune system's ability to produce antibodies and clear infections. The discovery opens up new avenues for treating cancer and autoimmune diseases by targeting this enzyme.
A study published in Nature Immunology has found that a specific type of immune cell, called T follicular regulatory cells, plays a crucial role in preventing autoimmune diseases like rheumatoid arthritis and systemic lupus erythematosus after viral infections. These cells prevent the generation of self-reactive antibody responses whil...
This study identifies the role of tumor-infiltrating B cells in promoting melanoma progression and resistance to therapy. The researchers found that depletion of B cells in the tumor microenvironment shows antitumor activity in patients with advanced metastatic melanoma.
Researchers have found a way to generate long-lasting immune cells that can respond to and stop HIV virus infection. The team demonstrated that a modified gp140 protein approach improves B-cell responses, boosting the ability of B-cells to make protective antibodies against HIV.
A new study reveals how the immune system avoids becoming cancerous by using a hair-trigger protein called Tia1. This protein controls the production of proteins needed to fix damaged DNA, allowing B cells to produce effective antibodies while preventing lasting harm.
Researchers at EPFL discovered key molecules driving lymphangiogenesis in response to worm infections, revealing a complex cross-talk between B cells and fibroblastic reticular cells.
A team of researchers has made a breakthrough discovery in understanding autoimmune diseases, revealing that rogue B cells can trigger an 'override' of the body's tolerance to its tissues. This finding sheds new light on epitope spreading, a hallmark aspect of autoimmune disease where the immune system attacks multiple organs and tissues.
A study led by Dr. Susana Minguet identified the protein Caveolin-1 as a key regulator of B cell organization and signaling. The team found that Caveolin-1 deficiency leads to autoimmune disease in animal models, highlighting a new strategy for treating autoimmunity.
Researchers have developed a new method to generate specific human antibodies in the laboratory using nanoparticles. This technique can produce high-affinity antibodies within days, offering potential for rapid therapeutic antibody production and accelerated vaccine development.
Scientists have found that human immune cells contain particles with neurotransmitters like dopamine, which play a crucial role in immune responses. This discovery opens the door to using available drugs to improve therapies for lymphoma, autoimmunity, and immunodeficiency disorders.
A recent study has made a breakthrough in understanding the autoimmune process that leads to type 1 diabetes, finding a way to protect beta cells from destruction. By targeting the activation of B cells, researchers were able to prevent diabetes in non-obese diabetic mice.
A research lab at the University of Kansas is analyzing human immune responses to develop an effective vaccine or drug therapy against Epstein-Barr Virus. By studying B cells, researchers aim to understand why some people are protected from EBV-associated diseases while others suffer from health issues.
Researchers at National Jewish Health have identified Age-associated B Cells (ABCs) as a key driver of autoimmune diseases such as lupus and Crohn's disease. The study found that ABCs cause the immune system to attack organs and tissues, leading to chronic inflammation and tissue damage.
A preliminary study suggests that removing Epstein-Barr virus-infected B cells and boosting the immune system may improve symptoms of multiple sclerosis. Three participants showed significant improvements, including one person with secondary progressive MS who was able to walk without assistance for the first time in 20 years.
Researchers found that strokes damage immune cells, making patients more susceptible to life-threatening infections like pneumonia. Therapies targeting damaged immune cells or bypassing their dysfunction could help recover from stroke, the study suggests.
Researchers at Osaka University discovered how specific genes regulate B cell cycling in germinal centers. They found that Foxo1 promotes B cell proliferation, but its activation is associated with lymphomas. Reviving BATF levels recovered the proliferation of Foxo1-deficient B cells.
A research group at Kobe University has discovered a potential new cancer treatment that activates cancer-engulfing cells. The treatment uses an antibody to activate macrophages, which can effectively eliminate cancer cells. This discovery could lead to the development of new and more effective cancer treatments.
Belgian scientists discovered protein Taok3 plays a key role in B cell development, leading to new molecular therapies for genetic conditions, asthma and diabetes. Mice genetically lacking Taok3 developed fewer type B immune cells, making them more susceptible to bacterial infections.
A new subset of helper T-cells, called peripheral helper T-cells (Tph cells), has been identified as a key player in the development of rheumatoid arthritis. These genetically distinct T-cells are found in tissues affected by RA and can induce plasma cell differentiation and inflammation.
Scientists have discovered that GSK3 plays a crucial role in controlling B cell metabolism, adapting to varying energy needs. The study found that GSK3 limits metabolic activity in circulating B cells while slowing glycolysis and production of mitochondria in proliferating B cells in germinal centers.
A team led by Prof Dr Aiden Haghikia and Prof Dr Ralf Gold report two patients who developed severe symptoms under alemtuzumab, a common MS treatment. The researchers successfully treated the side effects with a new algorithm that could benefit other patients worldwide.
Researchers found that B cells can capture proteins from pathogens and the body's own cells, leading to autoimmune inflammation. This error in protein uptake can trigger autoaggressive T cells, potentially causing autoimmune diseases.
Researchers at Cornell University have created a modular immune organoid that can replicate the anatomical structures found within lymph nodes. The 3-D organoid enables quicker and more plentiful replication of B cells, which are antibody-producing lymphocytes.
Researchers at Wayne State University have made a groundbreaking discovery about B lymphocytes and their role in preventing preterm birth. The study found that these cells produce molecules to suppress uterine inflammation and premature birth, potentially leading to new therapeutic approaches.
Researchers at UTMB engineered Ebola virus variants to study the components disabling the human immune system. The study found that IIDs promote replication of viral particles in cells and counteract the activity of immune cells.
Researchers discovered that Immunoglobulin D (IgD) keeps 'traitor cells' in lockdown, preventing auto-antibodies from damaging body tissues. IgD promotes the formation of germinal centres, allowing these cells to target invaders when needed.
Researchers found that adrenergic nerves control the daily cycle of immune cell trafficking, with T and B cells accumulating in lymph nodes during the day. This circadian pattern regulates the immune response, making mice more susceptible to infection when injected with antigens at night.
A team of researchers at Tokyo Medical and Dental University has identified a molecule called CD72 that prevents the immune system from mistakenly reacting to a component of the body's own cells. This breakthrough could lead to new treatments for systemic lupus erythematosus (SLE), a disease associated with inflammation of various organs.
Researchers at the University of Alabama at Birmingham have found that neonatal vaccination with certain bacteria can prevent adult asthma in mice. The protective effect is due to the selection of specific immune system B cells that produce IgA antibodies, which bind and inhibit allergens before triggering asthma.
A new program called CrispRGold helps scientists identify the most effective and specific RNA sequences for CRISPR-Cas9 system. This allows for efficient inactivation of genes in primary cells, enabling researchers to discover new genes involved in immune cell regulation.
Scientists at the University of Basel discovered that chronic viral infections lead to an inadequate immune response due to prolonged inflammation. This hasty reaction by B cells produces antibodies quickly but also leads to their rapid depletion, resulting in a short-lived and unsustainable defense against the virus.
Researchers have identified HDAC7 as a transcriptional repressor involved in B lymphocyte generation and identity. The study reveals that HDAC7 is essential for B cell development, maintaining its lymphoid identity by silencing lineage-inappropriate genes.
A new approach to treat cancer involves depleting CAR T cells after treatment, permanently restoring healthy B cell levels. Researchers created CD19-targeting CAR T cells with an additional EGFR targeting mechanism, eliminating tumors and reversing B cell aplasia in mice.
Researchers at The Scripps Research Institute (TSRI) found that members of a cluster of microRNAs work together throughout the stages of immune cell generation. Different miRNAs dominate different stages as disease-targeting immune cells develop, guiding the development of therapies against autoimmune diseases.
Researchers have identified three types of vaccine-induced antibodies that can neutralize diverse strains of influenza virus, which could guide development of a universal flu vaccine. The discovery provides clear evidence that these antibodies can be induced by a vaccine, making them a potential basis for a universal flu vaccine.
Researchers at the University of Alabama at Birmingham have identified a quality-control checkpoint in pre-B cells that restricts the range of antibodies produced by mature B cells. The discovery has potential implications for making vaccines more potent.
A team of researchers has identified the mechanisms behind excessive antibody production in chronic infections, discovering a link between B-cell activation and type 1 interferons. Proteins like endosomal TLRs trigger proinflammatory responses, leading to increased B-cell antibody production and potentially exacerbating conditions.
Scientists develop CAR-fused T cells that recognize abnormal B cells in autoimmune diseases like pemphigus vulgaris, reducing symptoms and promoting long-lasting effects.
Scientists at the University of Pennsylvania have developed a new therapy that selectively targets antibody-producing cells causing autoimmune disease, without harming the rest of the immune system. The treatment uses engineered T cells with an artificial receptor to bind to and destroy harmful B cells producing antibodies.